Search

A recent study conducted at the University of Rochester School of Medicine and Dentistry explored the inhibition of protein kinase D (PKD) and its substrate phosphatidylinositol-4 kinase III beta as a potential strategy to limit the replication of common human coronaviruses. The research suggests that targeting PKD and PI4KIIIb could serve as novel antiviral targets for human coronaviruses, potentially offering new avenues for treatment. This study sheds light on the role of PKD in the viral life cycle and highlights the importance of further investigation into these potential therapeutic targets. [Extracted from the article]

A patent application by inventors from the US proposes a system for pathogen detection, focusing on the early identification of SARS-CoV-2 to prevent the spread of COVID-19. The system includes a sensor, processor, and memory to detect changes in conductivity indicating the presence of pathogens. The invention utilizes graphene-based sensors with antibodies to detect antigens, aiming to provide rapid and accurate on-site diagnosis for effective prevention strategies. [Extracted from the article]

A patent application titled "Uses of Propranolol for Managing Viral Infections" was published online, highlighting the potential of propranolol in treating or preventing viral infections, including coronaviruses like SARS-CoV-2. Propranolol, traditionally known as a beta-blocker, has shown antiviral activity and may be administered in combination with other antiviral agents. The application emphasizes the need for improved therapies for viral infections and explores the use of propranolol in pharmaceutical compositions to address this need. [Extracted from the article]

The document discusses the issuance of a patent to Kinsa Health LLC for systems and methods for contagious illness surveillance and outbreak detection. The patent aims to leverage user data from a network of temperature sensing probes to identify increased transmission of illness before traditional healthcare systems can detect it. By focusing on underserved populations and utilizing real-time data, the patent seeks to provide early signals of infectious disease outbreaks. The patent outlines a system that can generate illness signals for different population nodes based on user data collected from mobile computing devices. [Extracted from the article]

The patent application "Genetically Engineered Cell-Derived Vaccines" discusses the development of vaccines against infectious diseases, particularly focusing on coronaviruses like SARS-CoV-2. The application highlights the use of genetically engineered cells to express antigens and induce immune responses, aiming to create effective and targeted vaccines with reduced side effects. By utilizing cell-derived vesicles induced from engineered cells, the inventors propose a novel approach to vaccine development that could potentially address the challenges posed by emerging strains of viruses like SARS-CoV-2. [Extracted from the article]

A patent has been issued for an infection risk mapping device, method, and computer-readable storage medium by Fujifilm Corporation. The invention aims to prevent the spread of infectious diseases, particularly focusing on asymptomatic carriers and individuals in the incubation period of COVID-19. The device acquires position and vital information of users to determine infection risk, specify risk places, and distinguish between asymptomatic carriers and confirmed infected individuals. The technology provides a novel approach to mapping infection risk and offers recommendations for monitoring, testing, and cleaning to prevent disease spread. [Extracted from the article]

A patent application titled "Methods Of Diagnosing, Prognosing, And Treating Multisystem Inflammatory Syndrome In Children (Mis-C) And Severe Covid-19, And Apparatuses Thereof" was published online on October 17, 2024, by inventors Gennaro, Maria L.; Guzman Rivera, Jeisac; Moore, Dirk Foster. The application focuses on detecting biomarkers associated with MIS-C and severe acute COVID-19 in pediatric populations to enable early diagnosis and proper treatment. The patent application outlines methods, uses, and apparatuses for diagnosing, prognosing, and treating MIS-C and severe acute COVID-19, emphasizing the importance of sensitive assays for early detection. [Extracted from the article]

A recent study from Staten Island University Hospital discusses a case of a 60-year-old white male with respiratory symptoms and cardiac tamponade caused by hantavirus. The patient had occupational exposure to rat droppings and urine, leading to positive hantavirus IgG and IgM antibodies. Despite initial symptoms, the patient was discharged asymptomatic after supportive management, with no recurrence of symptoms after two weeks. This research sheds light on the diagnostic challenges posed by hantavirus-induced cardiac tamponade. [Extracted from the article]

A patent application by inventors from the University of Vermont and State Agricultural College has been made available online, focusing on antibodies to the coronavirus SARS-CoV-2. The application details methods of inducing an immune response or treating coronavirus infections by administering specific antibodies. The document provides insights into the epidemiology, genetics, and treatment options for COVID-19, emphasizing the need for safe and effective prophylactic and treatment measures. [Extracted from the article]

A patent application titled "Sars-Cov-2-Specific T Cell Receptors And Related Materials And Methods Of Use" was published online on October 3, 2024, by inventors from Baltimore and Brookeville, Maryland. The application aims to provide new therapies for treating SARS-CoV-2 (COVID-19) by offering methods, compositions, and kits for treating and preventing the virus. The patent application includes details on T cell receptors, nucleic acid molecules, vectors, engineered cells, and compositions for diagnosing, treating, and monitoring COVID-19. The inventors seek to address the global morbidity and mortality caused by the COVID-19 pandemic through innovative therapeutic approaches. [Extracted from the article]

The patent application titled "Coronavirus Rapid Diagnostics" by inventors Abudayyeh, Gootenberg, and Zhang aims to revolutionize disease diagnosis and monitoring by rapidly detecting nucleic acids with high sensitivity and specificity using a portable platform. The application focuses on detecting the novel coronavirus, SARS-CoV-2, which causes COVID-19, emphasizing the importance of early and accurate testing to combat the spread of the virus. The platform described in the application utilizes CRISPR enzymes and isothermal amplification reagents to detect target polynucleotides in samples, offering a simpler and more efficient solution to address testing challenges during outbreaks. [Extracted from the article]

A report from Stellenbosch University in South Africa discusses the findings of research on the long-term effects of COVID-19. The study highlights the broad range of symptoms and organ damage that can occur in individuals with long COVID, including asymptomatic cases and acute events such as heart attacks or strokes. The research emphasizes the role of vascular dysfunction in these symptoms and explores potential therapeutic interventions. The study underscores the importance of early intervention to prevent long-term vascular and cellular dysfunction. [Extracted from the article]

A patent application titled "Compositions And Methods For The Prevention And/Or Treatment Of Covid-19" has been published online. The inventors have developed nucleic acid vaccines, compositions, and formulations for preventing and treating COVID-19. These vaccines contain polynucleotides that encode structural proteins of the SARS-CoV-2 virus, such as the spike protein. The vaccines can induce an immune response, including the production of antibodies and T-cells, and can be administered through intramuscular injection. The patent application provides detailed information on the nucleic acid sequences, dosages, and administration schedules for the vaccines. [Extracted from the article]

A patent application has been filed for a peptide that has shown anti-viral activity against the SARS-CoV-2 virus, including its mutant strains. The peptide, developed by inventors from Tokyo Medical and Dental University in Japan, targets the receptor binding domain (RBD) of the virus. It consists of two helix structures and has a stable three-dimensional structure, making it easily synthesizable and soluble in water or buffer solutions. The patent application provides specific amino acid sequences for the peptide, as well as information on how to produce an anti-viral agent using the peptide. [Extracted from the article]

A patent application titled "Wearable Collector for Noninvasive Sampling of Exhaled Breath Biomarkers, Pathogens or Viral Loads" has been published online. The invention aims to address the challenges of diagnosing COVID-19 by providing a wearable breath-based noninvasive sampler patch that can collect large quantities of viruses over prolonged periods of time. The device is compatible with any mask or protective equipment and can be made in large quantities. It utilizes a flexible substrate, a double-sided adhesive, and a porous membrane to collect biomarkers, pathogens, or viral loads from breath-derived droplets. The invention offers advantages such as personal use, non-invasiveness, low cost, and scalability. [Extracted from the article]

A patent application has been submitted for a system and methods for the detection of viral infections, specifically focusing on coronaviruses like SARS-CoV-2. The system involves collecting a small sample of biological fluid and using a viral test cassette to detect the presence of the virus or specific antibodies. The invention aims to provide a rapid and efficient means of detecting viral infections, including COVID-19, in community settings. The patent application also mentions the need for effective detection methods for other viral infections such as Ebola and yellow fever. [Extracted from the article]

A patent application titled "Antibodies to SARS-CoV-2" has been published by the US Patent and Trademark Office. The application, filed by inventors from Atreca Inc., discusses antibodies that can inhibit the binding of the SARS-CoV-2 virus to cells and reduce infection. The antibodies target various variants of the virus, including Alpha, Beta, Gamma, Delta, Epsilon, Mu, and Omicron. The application also provides information on COVID-19 symptoms, illness categories, current treatment options, and the need for safe and effective prophylactic and treatment options. It describes the use of antibodies in inhibiting virus binding, reducing infection, inducing an immune response, treating infected patients, and identifying infected patients. The application also includes details on recombinant nucleic acids, expression vectors, host cells, and methods for producing and identifying antibodies with anti-viral activity. The patent application was filed by Jason Botten, Daniel Eric Emerling, Shaun M. Lippow, Ngan Nguyen Atkins, Annalis Whitaker, and Katherine L. Williams on March 24, 2022. [Extracted from the article]

A patent application has been submitted for the invention of T cell epitopes that provide broad protective immunity against multiple species of coronaviruses, including SARS-CoV-2. The invention involves peptides and proteins that can elicit a T cell response to the coronavirus and can be used in an immunogenic formulation with an adjuvant. This is significant in the context of the ongoing COVID-19 pandemic and the emergence of new variants. The patent application discusses a composition that can detect the presence of a coronavirus or an immune response related to coronavirus infections, vaccines, or therapies. It includes various amino acid sequences and can be formulated with adjuvants and modulators of immune response. The application also describes methods for detecting coronavirus-specific T cells and measuring their activity. For more information, please refer to the full patent application. [Extracted from the article]

A patent application titled "Methods Of Using Probenecid For Treatment Of Coronavirus Infections" has been published online. The inventors propose using probenecid, a medication used to treat gout, as a potential treatment for coronavirus infections, including COVID-19. The method involves administering probenecid or a pharmaceutically acceptable salt thereof to reduce viral replication and alleviate symptoms associated with the disease. The patent application also mentions the classification of COVID-19 as a betacoronavirus within the same species as the SARS-CoV virus responsible for the 2002-2003 pandemic. The inventors suggest that probenecid could be administered orally, parenterally, topically, or mucosally, and could be used preventatively or therapeutically. [Extracted from the article]

A patent application has been submitted by Olaleye, Omonike A. from Texas Southern University for a composition and method to inhibit SARS-CoV-2 infection. The application acknowledges the global impact of the pandemic and the limited treatment options available. The proposed method suggests the use of compounds from the 8-hydroxyquinoline structural class, along with clinically approved active agents, to inhibit or ameliorate SARS-CoV-2 infection. The method focuses on reducing the activity of angiotensin converting enzyme 2 (ACE2) to disrupt the interaction between ACE2 and the Spike (S) glycoprotein of the virus, thereby reducing viral infectivity. The composition can be administered in various forms for ease of use. [Extracted from the article]

A patent application titled "Compositions And Methods For Debulking Virus Or Microorganism Load In The Oral Cavity" has been published online by the US Patent and Trademark Office. The patent application, filed by inventors Henry Daniell and Robert P. Ricciardi, aims to address the need for compositions and methods that effectively reduce viral and microbial load in the oral cavity. The method involves orally administering a composition containing a trapping molecule that binds to proteins or glucans on the surface of viruses or microorganisms, thereby reducing their load in the oral cavity. The invention focuses on reducing transmission, recovery time, and complications associated with viral and microbial infections. The patent application specifically mentions the potential use of the method for reducing SARS-CoV-2 viral load. The inventors propose using chewing gum as a carrier for the composition. [Extracted from the article]

A patent application has been submitted for a synergistic phytoextract formulation that has anti-inflammatory properties. The formulation includes phytoextracts from Elettaria cardamomum, Salvia rosmarinus, and piperine extract. The active molecule 1,8 Cineol found in the phytoextracts has muscle relaxant, anti-inflammatory, and analgesic effects. The formulation is intended for oral administration and may have anti-viral and anti-bacterial properties. The patent application aims to develop a natural herbal formulation for COVID-19 patients to aid in their recovery without harmful side effects. [Extracted from the article]

A patent application has been submitted for a portable diagnostic platform that can quickly detect biomarkers in fluid samples like blood, saliva, or nasal fluid. The platform consists of a sensing device with a piezoelectric material and disposable sensor cartridges that can detect specific antibodies. Connected to an electronic reading platform and a computing device, the device can determine the presence of biomarkers within 10 minutes. The biomarkers can indicate the presence of diseases such as COVID-19, MERS, or SARS, and the patent application also includes methods for predicting the existence or progression of a disease based on the biomarker data. [Extracted from the article]

The article reports on the issuance of patent number 12053555 for a new ultraviolet-C (UV-C) disinfecting device designed for use in aircraft and other confined spaces. Topics discussed include the challenges of disinfecting aircraft interiors, the use of UV-C light for effectively eliminating viruses, and the device's design to ensure safety and compliance while operating in occupied spaces.

The article focuses on a patent application for methods of detecting respiratory diseases using biomarkers in exhaled breath. Topics include the use of volatile organic compounds (VOCs) like Acetone and 1-Propanol for disease detection, the potential for rapid and non-invasive screening, and the inclusion of various other biomarkers in the diagnostic process.

The article focuses on a patent application for a system that predicts the presence of molecules, such as SARS-CoV-2, using chemical sensors. Topics include the measurement and processing of sensor data, the use of principal component analysis, and the integration of communication technologies like radio-frequency antennas.

The article reports that new research from the University of Washington provides insights into the genomic epidemiology and evolution of rhinoviruses. Topics include the sequencing of rhinovirus genomes to explore viral evolution during different epidemiological periods, the detection of intergenotypic recombination and genotype cluster swapping, and the association between symptoms and viral load without correlating with specific rhinovirus species or genotypes.

A patent application has been submitted for the use of the Ectromelia virus in cancer immunotherapy and vaccines. The Ectromelia virus is a virus that only affects mice and is harmless to other species, including humans. The virus can be easily modified genetically and used as a vaccine vector. The application suggests using the Ectromelia virus to express different proteins, such as cancer-specific antigens and viral antigens like the spike antigen of SARS-CoV-2. The goal of this research is to develop better methods and compositions for cancer immunotherapy and vaccination against viral infections. The patent application provides detailed information about the use of a recombinant ectromelia virus (ECTV) vector for cancer treatment and vaccines, including the administration of a vaccine containing the ECTV vector to stimulate an immune response in a patient. The vector can contain genetic sequences that encode various antigens, including those specific to cancer and viral infections like SARS-CoV-2. The method described in the patent application can be used to treat cancer and viral infections, including SARS-CoV-2. The application includes specific claims and descriptions of the invention. [Extracted from the article]

The USPTO has published a patent application titled "Medium Molecular Weight Heparin For Use In The Treatment Of Endotheliopathy," which explores the role of endothelial cells in regulating blood flow and maintaining homeostasis. The application emphasizes the significance of endothelial dysfunction, or endotheliopathy, in various diseases, including COVID-19. It suggests the potential use of medium molecular weight heparin as a treatment for endotheliopathy, specifically targeting the impaired function of endothelial cells. The application provides background information on heparin and its interaction with von Willebrand Factor (VWF) in the context of endothelial dysfunction. It also discusses the potential benefits of this treatment for patients with diseases such as COVID-19, cancer, cardiovascular disease, and bacterial infections. The patent application includes detailed claims and additional information for further exploration. [Extracted from the article]

A study conducted at AHEPA University Hospital in Thessaloniki, Greece, aimed to assess the prevalence of syphilis among people with HIV engaging in high-risk sexual behavior, determine the stage of syphilis, and evaluate treatment efficacy. The study found that 9.4% of the cohort of 991 participants were diagnosed with syphilis, with the majority of cases being asymptomatic latent syphilis. Men who have sex with men and younger individuals had higher rates of co-infection. The study concluded that there is an alarming incidence of syphilis among people with HIV engaging in high-risk sexual behavior, particularly among younger men who have sex with men. Treatment with benzathine penicillin G and doxycycline showed promise, especially in settings with penicillin shortages or patient allergies. [Extracted from the article]

A patent application titled "Compositions And Methods For Mucosal Vaccination Against Sars-Cov-2" has been published online. The inventors propose using the FcRn receptor to deliver SARS-CoV-2 spike antigens and induce protective immunity against SARS-CoV-2 infection. The peptides described in the patent application consist of a monomeric Fc fragment of an immunoglobulin recognized by FcRn, a SARS-CoV-2 antigen (such as the spike protein), and a trimerization domain. The inventors suggest that mucosal vaccination, specifically intranasal delivery, could be an effective approach to prevent SARS-CoV-2 infection and reinfection. [Extracted from the article]

The patent application titled "Methods Of Stratifying And Treating Coronavirus Infection" presents a method for treating COVID-19 infections caused by the SARS-CoV-2 virus. The method involves identifying indicators of infection in a sample from a patient and comparing them to control samples to determine the severity of the infection. Based on the severity, appropriate treatments can be administered. The patent application suggests using antiviral, antibiotic, or cholesterol biosynthesis inhibitor drugs for treatment and also explores the use of immune-based therapies. The goal of the method is to provide personalized treatments based on the individual's infection severity. [Extracted from the article]

Hyperspectral Corp. has been issued a patent for systems and methods for screening asymptomatic virus emitters. The patent describes a system that uses light sources, a sample device, a vortex mask, a detector, and a processor to detect and measure wavelength intensities from a biological sample. The system compares the measurements to a set of reference measurements and provides an alert if a subset of the measurements indicates the presence of a pathogen. The invention aims to address the challenges of wide-scale screening for viral infections by providing a faster and more accurate testing method. [Extracted from the article]

A patent application has been submitted for a probiotic composition that could potentially be used to treat COVID-19. The application discusses a clinical trial that tested the safety and effectiveness of a combination of Lactobacillus plantarum and Pediococcus acidilactici in adults with SARS-CoV-2 and COVID-19. The data presented in the application shows that the probiotic composition had positive effects on remission rates, viral load, antibody production, and symptom duration. The application also emphasizes the importance of specific strains of probiotics and the potential benefits of inducing certain immune responses to combat the virus and prevent lung damage. [Extracted from the article]

A patent application has been made available online for a nasal swab apparatus and method for applying a cleaning solution. The inventors stress the importance of nasal hygiene in preventing the spread of viruses and bacteria in the nasal cavity. They propose a nasal swab device that includes a cleaning solution and a guard to ensure proper placement in the nose. The device consists of two pre-saturated swabs, with one for cleaning and the other for sanitizing. It is portable, disposable, and can be used without medical assistance or running water. The patent application includes claims related to the composition and packaging of the device. [Extracted from the article]

A patent application from the Allen Institute has been released, providing information on molecular signatures of long-term COVID-19 and potential treatments. The application emphasizes the importance of studying the immune response in mild COVID-19 cases to identify key immunological mechanisms and predict outcomes such as post-acute sequelae of SARS-CoV-2 infection (PASC). The patent application also outlines methods for diagnosing and classifying chronic infections and autoimmune diseases, as well as treating symptoms in diagnosed individuals. The molecular signatures include biomarkers and proteins associated with inflammation and immune response. These methods may be particularly useful for understanding and addressing the long-term effects of SARS-CoV-2 infection. [Extracted from the article]

This document is a patent application for a method of diagnosing respiratory viral infections. The method involves obtaining a respiratory sample from a patient and measuring the expression levels of specific biomarkers in the sample. A viral score is generated based on the measured expression levels, and if the viral score exceeds a threshold value, it indicates that the patient has a viral infection. The patent application also includes claims for test kits for detecting the expression levels of the biomarkers. The biomarkers mentioned in the patent application include IFITM1, TLNRD1, CDKN1C, INPP5E, and TSTD1. The patent application was filed on May 11, 2022, and posted on July 4, 2024. [Extracted from the article]

A recent study conducted at the University of Washington Medical Center has examined the genomic epidemiology and evolution of rhinovirus in western Washington State. Rhinoviruses are known to cause the common cold, but the severity of infection can vary. The study analyzed 1,078 rhinovirus genomes from symptomatic and asymptomatic individuals during two distinct periods: when the COVID-19 pandemic affected the circulation of other respiratory viruses, and when seasonal viruses reemerged with severe outbreaks of RSV and influenza. The researchers found high diversity and co-circulation of genotypes within each rhinovirus species, highlighting the dynamic nature of rhinovirus genomic epidemiology. The study also emphasized the importance of investigating correlations between rhinovirus genotypes and serotypes to understand long-term immunity and cross-protection. [Extracted from the article]

The US Patent and Trademark Office has published a patent application titled "Respiratory Virus Combination Vaccines" by ModernaTX Inc. The application describes a combination vaccine that includes multiple messenger ribonucleic acid (mRNA) polynucleotides encoding antigenic polypeptides from various respiratory viruses, such as influenza, coronaviruses, and respiratory syncytial virus (RSV). The vaccine is delivered using lipid nanoparticles. The disclosure highlights the need for effective and safe vaccines against respiratory viruses, which cause significant global illness and death. For more information, please refer to the full patent application. [Extracted from the article]

A patent has been issued for carbohydrate-binding small molecules with antiviral activity. The patent focuses on the Flaviviridae family of viruses, including Zika, West Nile, hepatitis C, dengue, yellow fever, and the coronavirus. The inventors highlight the urgent need for novel agents to treat Zika virus (ZIKV) and explore molecules that inhibit ZIKV using unconventional strategies. The patent describes the use of synthetic carbohydrate receptors (SCRs) that can disrupt the viral docking process and potentially prevent or mitigate ZIKV infection. These SCRs have shown anti-FLV activity by binding glycans on the viral envelope protein or disrupting interactions between host cell glycans and glycan binding proteins on the viral envelope. [Extracted from the article]

A patent application has been submitted for the use of peptides derived from the SARS-CoV-2 virus in diagnosing COVID-19. The peptides are linear epitopes, meaning they are recognized by antibodies based on their amino acid sequence. This method aims to improve the accuracy of serology diagnostics for SARS-CoV-2 infection, as existing antibody tests can produce false positives due to shared antigens with other coronavirus strains. The patent application includes specific peptide sequences from the S, N, and ORF1 proteins of the virus. [Extracted from the article]

A patent application has been filed for a herbal extract formula that shows potential in treating coronavirus infections, including COVID-19. The formula consists of extracts from different plant families and aims to inhibit, prevent, and treat coronaviruses. It is designed to increase bioavailability and stability. It is important to note that the patent application has not been assigned to a specific company or institution. The composition has shown promising results in suppressing viral protease, inhibiting spike protein binding, reducing viral replication, and decreasing inflammation. The application also outlines methods for administering the formula to treat or prevent coronavirus infections. [Extracted from the article]

A patent has been issued to Hyperspectral Corp. for systems and methods that use diversifiers to reduce noise and screen nutrients or chemical compositions. The patent addresses the need for efficient and accurate testing methods for viral infections, such as COVID-19, that can be used for wide-scale screening. The system described in the patent involves using light sources, sample devices, vortex masks, detectors, and processors to detect and measure wavelength intensities impacted by the sample. The patent claims include the system configuration and methods for comparing and analyzing measurement results to identify categories and filter out noise. [Extracted from the article]

A patent application has been made available online for a method and system that can detect proteins, organic compounds, and pathogens in exhaled air samples. The system includes various components such as a pump, cooling chamber, injector unit, inert gas source, and test chamber. The method involves pumping an exhaled air sample into a cooling chamber, mixing it with an inert gas, heating the mixture, and then analyzing it in a test chamber. This method offers a non-invasive and high-throughput alternative to current diagnostic methods. NewsRx LLC is a reliable source of fact-based news reports that cover research and discoveries from around the world. These reports are copyright protected and provide valuable information for library patrons conducting research on specific topics. They are also culturally sensitive and respectful of diverse perspectives, making them a useful resource for those seeking accurate and unbiased information. [Extracted from the article]